Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder
National Institute for Clinical Excellence
Record ID 32003001116
English
Authors' objectives:
To provide guidance on the use of olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder.
Authors' recommendations:
Guidance:
1.1 Olanzapine and valproate semisodium, within their licensed indications, are recommended as options for control of the acute symptoms associated with the manic phase of bipolar I disorder.
1.2 Of the drugs available for the treatment of acute mania, the choice of which to prescribe should be made jointly by the individual and the clinician(s) responsible for treatment. The choice should be based on an informed discussion of the relative benefits and side-effect profiles of each drug, and should take into account the needs of the individual and the particular clinical situation.
1.3 In all situations where informed discussion is not possible advance directives should be taken fully into account and the individuals advocate and/or carer should be consulted when appropriate.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=86769
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Costs and Cost Analysis
- Antipsychotic Agents
- Bipolar Disorder
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.